#healtheconomics — Public Fediverse posts

https://www.europesays.com/unitedstates/35745/ ‘Medicare for All’ to ‘Take on Big Pharma’: What’s Behind Healthcare Slogans | Billings News #cost #election #Health #HealthCare #HealthCarePricesInTheUnitedStates #HealthEconomics #HealthInsurance #Healthcare #HealthcareEconomics #Medicare(unitedStates) #Medication #MedicationCosts #PersonalFinance #PharmaceuticalIndustry #PrescriptionDrug #ServiceEconomy #SinglePayerHealthcare #SocialPrograms #tncen

https://www.europesays.com/unitedstates/35097/ ‘Medicare for All’ to ‘Take on Big Pharma’: What’s Behind Healthcare Slogans | Spokane News #cost #election #Health #HealthCare #HealthCarePricesInTheUnitedStates #HealthEconomics #HealthInsurance #Healthcare #HealthcareEconomics #Medicare(unitedStates) #Medication #MedicationCosts #PersonalFinance #PharmaceuticalIndustry #PrescriptionDrug #ServiceEconomy #SinglePayerHealthcare #SocialPrograms #tncen

Genomic secondary findings can shift treatment costs sharply—budget-impact models should map the cascade before screening expands.

https://www.mattheneus.com/editorial/pubmed-genomic-secondary-findings-budget-impact-treatment-cost-concentration-2026-10-10

#HTA #HealthEconomics #RegulatoryAffairs

Outcome rankings in post-stroke shoulder-hand syndrome rehabilitation can shift by endpoint, while wide prediction intervals reveal the uncertainty decision-makers need to see. https://www.mattheneus.com/editorial/frontiers-post-stroke-shoulder-hand-syndrome-rehabilitation-network-prediction-intervals-2026-09-23 #HTA #NMA #EvidenceSynthesis #HealthEconomics

Comparative evidence can fail even when a pivotal trial succeeds. The SMC declined inavolisib amid NMA and economic uncertainty.
https://www.mattheneus.com/editorial/smc-inavolisib-itovebi-non-recommendation-inavo120-nma-economic-uncertainty-2026-10-12

#HTA #NMA #EvidenceSynthesis #HealthEconomics

Scottish access decisions can hinge on how confidently trial evidence carries into local clinical practice. https://www.mattheneus.com/editorial/smc-itulazax-birch-pollen-rhinoconjunctivitis-tt04-value-extrapolation-2026-10-12 #HTA #EvidenceSynthesis #HealthEconomics

Poland’s AOTMiT supports named-patient import reimbursement for Mytelase when pyridostigmine is not tolerated. https://www.mattheneus.com/editorial/aotmit-mytelase-ambenonium-pyridostigmine-intolerance-import-reimbursement-2026-10-01 #HTA #HealthEconomics #RegulatoryAffairs

Coverage decisions need a clear threshold for how much real-world evidence bias is tolerable. #HTA #RWE #HealthEconomics
https://www.mattheneus.com/editorial/real-world-evidence-bias-threshold-coverage-evidence-development-2026-10-09

What makes medicine-price negotiation work? A review of 88 studies maps the policy mix and infrastructure countries need. https://www.mattheneus.com/editorial/pubmed-global-medicine-pricing-policy-mix-infrastructure-readiness-2026-10-10 #HTA #HealthEconomics #Pharma

New evidence review: guided-growth outcomes clarify correction and follow-up needs in paediatric genu valgum. https://www.mattheneus.com/editorial/sicot-genu-valgum-tension-band-plate-follow-up-correction-2026-10-08 #HTA #EvidenceSynthesis #HealthEconomics

Resistance training ranked highest for cognition across Alzheimer’s, Parkinson’s and MCI, though certainty remains low.\nhttps://www.mattheneus.com/editorial/frontiers-cognitive-exercise-network-alzheimer-parkinson-mci-low-certainty-2026-10-10\n#HTA #NMA #EvidenceSynthesis #HealthEconomics

Live-birth evidence can tell a different story from pregnancy rankings in chronic endometritis research. https://www.mattheneus.com/editorial/pubmed-chronic-endometritis-nma-live-birth-endpoint-hierarchy-2026-10-08 #HTA #NMA #EvidenceSynthesis #HealthEconomics

New South African modelling finds targeted PCV20 vaccination for older adults with HIV can offer a favourable balance of cost-effectiveness and budget impact.

https://www.mattheneus.com/editorial/human-vaccines-pcv20-south-africa-hiv-targeted-cost-effectiveness-budget-impact-2026-10-08

#HTA #HealthEconomics #RWE

When coinfections exceed chance, pooled prevalence can conceal the dependence structure that matters for evidence interpretation. #HTA #EvidenceSynthesis #HealthEconomics https://www.mattheneus.com/editorial/pubmed-malaria-schistosomiasis-coinfection-overdispersion-meta-analysis-2026-10-09

Thirty-three trials reveal why paediatric antiemetic networks need time-specific estimands for credible decisions. https://www.mattheneus.com/editorial/paediatric-antiemetic-nma-time-window-estimand-governance-2026-10-04 #HTA #NMA #EvidenceSynthesis #HealthEconomics

Phasing out low-value care takes more than identifying it: IQWiG’s evidence agenda maps how HTA can support deimplementation. https://www.mattheneus.com/editorial/iqwig-low-value-care-identification-deimplementation-evidence-agenda-2026-10-06 #HTA #EvidenceSynthesis #HealthEconomics

Germany’s burosumab assessment shows how evidence transfer to infants can fail when population relevance and clinical comparability remain uncertain. #HTA #HealthEconomics #RegulatoryAffairs https://www.mattheneus.com/editorial/iqwig-burosumab-infant-xlh-evidence-transfer-insufficient-2026-10-01

In CIDP evidence synthesis, feasibility checks on populations, outcomes and pooling should come before adjustment choices.

https://www.mattheneus.com/editorial/cidp-maic-feasibility-population-outcome-pooling-checks-2026-10-09

#HTA #MAIC #EvidenceSynthesis #HealthEconomics

Patient choice is gaining a stronger place in German health technology assessment. The G-BA has commissioned a decision aid for planned nasal septum and turbinate surgery. https://www.mattheneus.com/editorial/g-ba-nasal-septum-turbinate-surgery-patient-decision-aid-commission-2026-10-07 #HTA #HealthEconomics #RegulatoryAffairs